Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Core Insights - Ipsen S.A. has published its consolidated financial statements for the year 2025, providing a comprehensive overview of its financial performance and strategic direction [1] Financial Performance - The company reported a total revenue of €2.5 billion for 2025, reflecting a growth of 8% compared to the previous year [1] - Net income for the year was recorded at €500 million, which represents a 10% increase year-over-year [1] - The earnings before interest, taxes, depreciation, and amortization (EBITDA) margin improved to 30%, up from 28% in 2024 [1] Strategic Developments - Ipsen has focused on expanding its product portfolio, with significant investments in research and development amounting to €300 million, which is 12% of total revenue [1] - The company has also entered into strategic partnerships aimed at enhancing its market presence in emerging markets [1] Market Outlook - The management has provided guidance for 2026, projecting a revenue growth rate of 7-9%, driven by new product launches and market expansion initiatives [1] - Ipsen anticipates continued strong demand for its key therapeutic areas, particularly in oncology and rare diseases [1]